Spiriva (tiotropium bromide) is a prescription drug that’s used to treat COPD and asthma. The drug comes in an inhaler. It’s usually used once per day. Spiriva is a prescription drug that comes in two ...

Spiriva (tiotropium) is a prescription drug used to treat specific breathing conditions. Spiriva’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy ...

BOSTON (Reuters) - Spiriva, marketed by Pfizer and Boehringer Ingelheim, offered no advantage over an inhaled placebo for moderate-to-very-severe chronic obstructive pulmonary disease, or COPD, ...

LONDON, Sept 24 (Reuters) - Results of a clinical study to be presented next month show the blockbuster inhaled lung drug Spiriva, marketed by Pfizer and Boehringer Ingelheim, actually cuts heart risk ...

Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device. Spiriva Handihaler consists of Spiriva capsules and the Handihaler device. Spiriva capsules ...

Want to know what asthma feels like? Try a crushing bear hug. That’s what patients told Boehringer Ingelheim, informing its latest campaign for Spiriva Respimat as a treatment for asthma. In new TV ...

Tiotropium (as bromide monohydrate) 1.25mcg, 2.5mcg; per actuation; inh spray; contains benzalkonium chloride. Spiriva Respimat Inhalation Spray is supplied in a carton containing one Spiriva Respimat ...

Spiriva, a drug that is already widely used to treat chronic obstructive pulmonary disease, can provide significant relief of symptoms for adult asthmatics who have difficulty obtaining relief with ...

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...

In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...